Breaking News

A physician considers gratitude

January 25, 2026
avatar-torie-bosch
First Opinion editor

I've got my ice melt and I've got the bread and milk, so I'm pretty sure that the winter storm is going to end up a bust near me. If you're in the Philadelphia area, I'm sorry/you're welcome, depending on your point of view.

The "First Opinion Podcast" won't be back for several weeks, but STAT's Alissa Ambrose and I are already planning. Who would you like to hear on the show? Let me know.

Recommendation of the week: At the Atlantic, Dan Engber looked at the evidence behind the palate expander in pediatric orthodontics. Reading it brought up some trauma for me — I still wince at the memory of my mother turning the key once a week on my lower palate expander 35 years ago — but in a good way. I think.



JEFF PACHOUD/AFP via Getty Images

I ask my patients what they're grateful for. Recently, three of them cried

A doctor's simple question sparked unexpected tears — revealing fears about preventable illness, shrinking safety nets, and what gratitude really means now.

By Joseph Tucker


I'm a doctor who knows better — but I switched to an inferior drug to save money

Patients end up forgoing care or shouldering the burden of their health costs under high-deductible health plans.

By Amy Caggiula


A Goldilocks approach to centralization of high-risk pathogen research

Consolidating all risky pathogen research into a handful of federal laboratories is not the path to achieving stronger oversight.

By David Gillum, Anemone Franz, An Tran, and Kathleen M. Vogel


Adobe

Did my prostate cancer screening do more harm than good?

Editor's 15-year journey with low-risk prostate cancer shows how PSA screening in U.S. fuels overdiagnosis and overtreatment compared with other countries.

By Howard Wolinsky


I'm getting the HPV vaccine at 24. That's a problem

Even before the childhood vaccine schedule's update, doctors often overlooked the vaccine that can prevent cervical cancer.

By Anamika Shrimali


STAT+ | Excitement and wariness as FDA shifts to much more flexible cell and gene therapy oversight

The new "flexible" CGT oversight system could accelerate development — but it comes with risks for the whole field, and even the FDA itself.

By Paul Knoepfler


A donated human embryo is seen through a microscope at an IVF clinic in La Jolla, California.
Sandy Huffaker/Getty Images

It's time to translate vague unease around stem cell IVF into clear guardrails

Stem cells could be used to create eggs and sperm, opening the door to new possibilities — and new ethical conundrums.

By Zubin Master and Scott D. Rhodes


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying First Opinion? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments